3 models fit Concentra Group Holdings Parent Inc. Common Stock and they disagree: 0 of 3 land within 15% of the average.
Two or more of our models back this value.
Large premium(i)Bronze56
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, and Graham number.
ACCE opinionConcentra Group Holdings Parent Inc. Common Stock (CON)
Fair value (3 models)
$26.63
ACCE price target
$37.50
Rating
Overvalued
Horizon
12 months
Fair value published on 21 Oct 2026, 13:04 CEST; previously $35.22 since 17 Oct 2026, 00:00 CEST.
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Rating published on 21 Oct 2026, 13:04 CEST.
Price used: $39.25 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
47.4% above
-32.2% to fair value
ACCE score
74
out of 100
Analysts
100% buy
9 covering
P/E
25.3x
forward 21.3x
1-year return
+91.0%
Dividend yield
0.63%
Concentra Group Holdings Parent Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Concentra Group runs occupational health clinics, where it treats work-related injuries, performs physicals and drug screens, and provides medical services for employers, mostly under contract with workers' compensation carriers and self-insured employers. The moat is scale and density: it operates a large clinic network across many U.S. markets, and its contracted referral relationships with employers and carriers are hard to replicate one location at a time. Revenue growth of 10.0% is paired with a 19.3% operating margin and a 47.1% return on equity, which points to a business that is both expanding and converting that growth into profit. The forward P/E of 18.0 sits well below the trailing 24.2, so the market is pricing in earnings growth over the next year rather than paying for what has already been reported. For a concentrated book, the question is whether that earnings step-up holds up, and the reported numbers are a reasonable place to start that check.